The Steroid 17 Alpha Hydroxylase/17,20 Lyase pipeline drugs market research report outlays comprehensive information on the Steroid 17 Alpha Hydroxylase/17,20 Lyase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Steroid 17 Alpha Hydroxylase/17,20 Lyase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Metabolic Disorders which include the indications Metastatic Castration-Resistant Prostate Cancer (mCRPC), Hormone-Sensitive Prostate Cancer, and Cushing’s Syndrome. It also reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase targeted therapeutics development with respective active and dormant or discontinued products.
The Steroid 17 Alpha Hydroxylase/17,20 Lyase pipeline targets constitutes close to 11 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 3, 4, 1, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Steroid 17 Alpha Hydroxylase/17,20 Lyase overview
Steroid 17-alpha-hydroxylase/17, 20 lyase is an enzyme belonging to hydroxylase class that is encoded by CYP17A1 gene. It helps in conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. It catalyzes both the 17-alpha-hydroxylation and the 17, 20-lyase reaction. It is involved in sexual development during fetal life and at puberty.
For a complete picture of Steroid 17 Alpha Hydroxylase/17,20 Lyase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
